Xi Zhang - research works

Among ten medications for NIU, adalimumab accounted for the highest number of AEs reports (N=5,842), followed by infliximab (N=1,199), prednisone (N=749), and methotrexate (N=427).

Common AEs were observed in the present study.

For instance, AEs of infections (N=293) and endocrine disorders (N=47) were reported in prednisone.

We also found several AEs which had not been reported in NIU patients before, with splenomegaly as an example (ROR 95% CI lower bound: 4.66; IC025: 1.35; P<0.001).

Based on the use of immunotherapy, patients were divided into the RT+CT+ICI group (received brain radiotherapy combined with immunotherapy and chemotherapy, n=117) and the RT+CT group (received brain radiotherapy combined with chemotherapy alone, n=105).

Multivariable adjustments confirmed prolonged OS (HR 0.58, 95% CI 0.41-0.81, P = 0.002) and progression-free survival (PFS) (HR 0.72, 95% CI 0.53-0.98, P = 0.038) in the RT+CT+ICI group.

Although both groups experienced functional improvement after treatment, the chorioretinal group had significantly worse final BCVA at twelve months (median 0.80 versus 0.20 LogMAR; P = 0.005) and a higher overall complication burden (92.3% versus 25.0%; P < 0.001) than the intraretinal or preretinal group.

From 342 eligible patients, PSM created 122 well-balanced pairs ( n = 244).

The matched cohort demonstrated excellent covariate balance (all SMDs < 0.1).

S. leads in total citations, China suggests the most rapid recent growth.

Research hotspots may have evolved from foundational classification systems and instrumentation to evidence-based conservative management.

Recent frontiers (2022-2025) indicate a paradigm shift toward precision medicine, characterized by the emergence of "vertebral body tethering" (VBT) and "artificial intelligence" (AI).

GT willingness was positively associated with child age under 12 (OR, 1.61; P = 0.019), married status (OR, 5.94; P = 0.016), and IRD-related strife (OR, 3.61; P = 0.014), and negatively with parental severe vision impairment (OR, 0.19; P = 0.012).

Child gender predicted unwillingness rationale ( P = 0.002); parents of males cited apprehension about results, while parents of females cited cost.

Most parents indicated SR unwillingness (NC: 60.3%; ART: 52.2%), with greater willingness toward ART than NC ( P = 0.041).

In the present case, both biparietal diameter (BPD) and head circumference (HC) exceeded the 97th percentile by 32 + 1 week of gestation.

At 36 + 1 week, BPD remained above the 97th percentile, while HC was near it.

Genetic analysis revealed two novel heterozygous GCDH variants: c.492C > G and c.648G > A.

The scoping review identified six fetal GA-1 cases.

Of 41 included studies, most were rated at high or unclear risk of bias across Quality Assessment of Diagnostic Accuracy Studies 2 domains, predominantly in patient selection because of retrospective designs and nonconsecutive sampling, and in the index test domain because of post hoc threshold selection.

The interleukin (IL)-10 to IL-6 ratio (27 studies; 1370 patients; AUSROC, 0.98; sensitivity, 0.89; specificity, 0.98; I 2 = 61% and 69%, respectively; low certainty) showed no publication bias.

Higher odds of multimorbidity were associated with older age (Odds Ratio [OR] = 2.24; 95% Confidence Interval [CI] 1.81-2.76), female (OR = 1.32; 95% CI 1.20-1.45), receiving ≥ 3 social security benefits (OR = 1.64; 95% CI 1.09-2.48), and obesity (OR = 1.90; 95% CI 1.48-2.44).

Lower odds were associated with higher educational level (OR = 0.55; 95% CI 0.39-0.75), being physically active (OR = 0.66; 95% CI 0.56-0.77), better access to medical institutions (OR = 0.67; 95% CI 0.45-0.99) and beds (OR = 0.55; 95% CI 0.37-0.80).

A total of 137 patients completed the 3-months postoperative follow-up.

At 3 months, the mean binocular UDVA, UIVA, and UNVA were 0.017 ± 0.086, 0.061 ± 0.110, and 0.061 ± 0.103 logMAR, respectively.

Refractive predictability was high, with 84.62% of eyes within ±0.50 D of emmetropia.

Complete spectacle independence was reported by 96.90% of patients.

Corneal AEs occurred in all eight patients.

The mean time to visual impairment onset was 37.25 ± 5.90 days after trastuzumab botidotin initiation, with symptom severity peaking at 82.75 ± 14.26 days.

Trastuzumab botidotin caused dry eye in all patients (n = 8), resulting in reduced Schirmer's test results (from 8.94 ± 1.66 mm to 4.20 ± 1.58 mm), shortened tear break-up time (from 9.63 ± 1.21 seconds to 3.37 ± 1.61 seconds), and decreased tear meniscus height (from 0.23 ± 0.04 mm to 0.14 ± 0.02 mm).

Current management of coGVHD faces challenges, with frequent missed or misdiagnosed cases.

In external validation, the early warning AUROC was 83.45%, while diagnostic AUROCs across three external sites were all above 96.0%.

Unfavorable outcomes occurred in 420 patients (39.3%).

Higher AAR was associated with poor outcomes in the overall cohort (adjusted OR 1.34, 95% CI: 1.07-1.66).

However, significant effect modification by disease type was observed (P for interaction = 0.001).

Conversely, AAR showed no significant prognostic value in ICH ( p = 0.746) or aSAH ( p = 0.810).

JIA patients showed significantly higher median BS in all target joints, with the most significant differences in bilateral wrists (left wrist: median = 3.25, IQR = 1.35, P = 0.02; right wrist: median = 3.26, IQR = 1.5, P = 0.01).

The systemic features, including recurrent oral ulceration, multiform skin lesions and genital ulceration were weighted as 4 points, 3 points and 2 points, respectively.

Primary assessment was based on ocular features alone.

An ocular score ≥5 supported a BU diagnosis in patients without signs of granulomatous uveitis or evidence of sarcoidosis or syphilis.

However, comprehensive large-cohort analyses integrating genotype-phenotype correlations and functional mechanisms remain limited.

Pathogenic variants mainly comprised single-nucleotide variants and copy number variants.